Newborn screening for lysosomal storage diseases: An ethical and policy analysis

Journal of Inherited Metabolic Disease

Volumn 35, Issue 4, 2012, Pages 627-634

  Ross, Lainie Friedman ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GALACTOSYLCERAMIDASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ASSISTED VENTILATION; CONFERENCE PAPER; ENZYME REPLACEMENT; FABRY DISEASE; FIBROBLAST CULTURE; GENE MUTATION; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE POLICY; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYSOSOME STORAGE DISEASE; MEDICAL ETHICS; MUSCLE BIOPSY; NEWBORN SCREENING;

HUMANS; INFANT, NEWBORN; LYSOSOMAL STORAGE DISEASES; NEONATAL SCREENING; PARENTS; POLICY MAKING; PUBLIC HEALTH; TANDEM MASS SPECTROMETRY;

EID: 84863862780     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9435-0     Document Type: Conference Paper

References (61)

1. Alexander D, van Dyck PC (2006) A vision of the future of newborn screening. Pediatr 117(5 Pt 2):S350-S354 (Pubitemid 46071323)
2. American Academy of Pediatrics (AAP) Committee on Bioethics (2001) Ethical issues with genetic testing in pediatrics. Pediatr 107:1451-1455
3. Andermann A, Blancquaert I, Beauchamp S, Dery V (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin World Health Org 86 (4):317-319 (Pubitemid 351521860)
4. Andrews LL, Fullarton JE, Holtzman NA, Motulsky AG, and the Committee on Assessing Genetic Risks, Institute of Medicine (IOM) (eds) (1994) Assessing genetic risks: implications for health and social policy. National Academy Press, Washington, DC
5. Arnold GL, VanHove J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Gen Metab 96:85-90
6. ASHG/ACMG American Society of Human Genetics (ASHG)/ American College of Medical Genetics (ACMG) (1995) Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Amer J Hum Genet 57:1233-1241
7. Bailey DB, Beskow LM, Davis AM, Skinner D (2006) Changing perspectives on the benefits of newborn screening. Mental Retard Develop Disabil Res Rev 12:270-279 (Pubitemid 46053453)
8. Bashore L (2004) Childhood and adolescent cancer survivors' knowledge of their disease and effects of treatment. J Pediatric Onc Nurs 21:98-102
9. Canadian Paediatric Society (CPS) Bioethics Committee and the Ethics and Public Policy Committee, Canadian College of Medical Geneticists (2003) Guidelines for genetic testing of healthy children. Paediatr Child Health 8(1):42-45, Reaffirmed February 2010
10. Caniglia M, Rana I, Pinto RM et al. (2002) Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe's disease). Pediatr Transplant 6(5):427-431 (Pubitemid 35265196)
11. Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE (2010) Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 33:747-750
12. Chen LR, Chen CA, Chiu SN et al. (2009) Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr 155:271-275
13. Chien YH, Chiang SC, Zhang XK et al. (2008) Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatr 122(1):e39-e45
14. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL (2011) Later-Onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 158:1023-1027
15. Dajnoki A, Muhl A, Fekete G et al. (2008) Newborn screening for Pompe disease by measuring GAA activity using tandem mass spectrometry. Clin Chem 54:1624-1629
16. Duffner PK, Caggana M, Orsini JJ et al. (2009a) Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 40:245-252, discussion 253-5
17. Duffner PK, Jalal K, Carter RL (2009b) The hunger's hope Krabbe family database. Pediatr Neurol 40:13-18
18. Duffner PK, Caviness VS, Erbe RW et al. (2009c) The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 11:450-454
19. Erbe RW, Levy HL (2012) Neonatal screening. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR (eds) Emery and Rimoin's principles and practice of medical genetics, 6th edition, in press
20. Escolar ML, Poe MD, Provenzale JM et al. (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 352:2069-2081 (Pubitemid 40664308)
21. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ (2004) Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 50:1979-1985 (Pubitemid 39425833)
22. Gibson KM, Bennett MJ, Naylor EW, Morton DH (1998) 3-Methylcrotonyl- coenzyme A carboxylase deficiency in Amish/ Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. J Pediatr 132(3 Pt 1):519-523 (Pubitemid 28180262)
23. Hanley WB (2008) Finding the fertile woman with phenylketonuria. Europ J Obstet Gynec Repro Bio 137:131-135
24. Hoffmann B (2009) Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis (OJRD) 4(21):1-9
25. Hopkin RJ, Bissler J, Banikazemi M et al. (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 64(5):550-555
26. Hwu WL, Chien YH, Lee NC et al. (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G〉A (IVS4+919G〉A). Hum Mutat 30:1397-1405
27. Kemper AR, Hwu W-L, Lloyd-Puryear M, Kishnani PS (2007) Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatr 120:e1327-e1334 (Pubitemid 350085549)
28. Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM (2010) Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med 12:539-543
29. Kishnani PS, Howell RR (2004) Pompe disease in infants and children. J Pediatr 144(5 Suppl):S35-S43 (Pubitemid 38591273)
30. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, for the Infantile-Onset Pompe Disease Natural History Study Group (2006) A retrospective, multinational,multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-6
31. Kishnani PS, Corzo D, Nicolonio M et al. (2007) Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurol 68:99-109 (Pubitemid 46071892)
32. Kishnani PS, Goldenberg PC, DeArmey SL et al. (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26-33
33. Kokotos F (2009) The vulnerable child syndrome. Pediatr Rev 30:193-194
34. Krivit W, Shapiro EG, Peters C et al. (1998) Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 338:1119-1126 (Pubitemid 28227482)
35. Kumamoto S, Katafuchi T, Nakamura K et al. (2009) High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. Mol Gen Metab 97:190-195
36. Labrousse P, Chien YH, Pomponio RJ et al. (2010) Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 99:379-383
37. Li Y, Scott CR, Chamoles NA et al. (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785-1796 (Pubitemid 39298007)
38. Linthorst GE, Vedder AC, Aerts JM, Hollak CE (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353(1-2):201-203 (Pubitemid 40215447)
39. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217-222
40. Meikle PJ, Grasby DJ, Dean CJ et al. (2006) Newborn screening for lysosomal storage disorders. Mol Genet Metab 88:307-314 (Pubitemid 44107765)
41. Mendelsohn NJ, Messinger YHH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe's disease. N Eng J Med 360:194-195
42. Mercimek-Mahmutoglu S, Moeslinger D, Haberle J et al. (2010) Longterm outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab 100:24-28
43. Merk T, Wibmer T, Schumann C, Kruger S (2009) Glycogen storage disease type II (Pompe disease)-influence of enzyme replacement therapy in adults. Europ J Neurol 16:274-277
44. Moyer VA, Calonge N, Teutsch SM, Botkin JR, on behalf of the United States Preventive Task Force (2008) Expanded newborn screening: process, policy and priorities. Hast Cent Rep 38(3): 32-39
45. National Screening Committee (UK) (2011) Programme appraisal criteria: Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. On the web at: http://www.screening.nhs.uk/criteria. Last accessed November 25, 2011
46. Newborn Screening Task Force (2000) Serving the family from birth to the medical home: newborn screening: a blueprint for the future - a call for a National Agenda on State Newborn Screening Programs. Pediatr 106(2 Suppl):389-422
47. Petros M (2011) Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening? Genet Med. doi:10.1097/GIM.0b013e31823331d0
48. President's Council on Bioethics (2008) The changing moral focus of newborn screening. Government Printing Office, Washington DC
49. Rohrbach M, Klein A, Kohli-Wiesner A et al. (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751-757
50. Ross LF (2006) Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Amer J Med Genet 140A:914-922
51. Ross LF (2010) Mandatory versus voluntary consent for newborn screening? Kennedy Instit Ethics J 20:299-328
52. Rozenfeld PA (2009) Treatment and diagnosis. IUBMB (Internat Union Biochem Mol Bio) Life 61(11):1043-1050
53. Saito S, Ohno K, Sakuraba H (2011) Fabry-database.org: database of the clinical phenotypes, genotypes and mutant alpha-galactosidase structures in Fabry disease. J Human Genet 56:467-468
54. Salveson R (2011) Expansion of the New York State newborn screening panel and Krabbe disease: a systematic program evaluation. PhD Dissertation for the School of Nursing at Columbia University. On the web at: http://academiccommons. columbia.edu/catalog/ac:132317. Last accessed November 25, 2011
55. Spada M, Pagliardini S, Yasuda M et al. (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Amer J Hum Genet 79:31-40 (Pubitemid 43927374)
56. Strothotte S, Strigl-Pill N, Grunert B et al. (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91-97
57. Timmermans S, Buchbinder M (2010) Patients-in-waiting: living between sickness and health. J Health Social Behav 51:408-423
58. van Calcar SC, Gleason LA, Lindh H et al. (2007) 2-Methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. Wisconsin Med J 106(1):12-15 (Pubitemid 46294210)
59. Wilcken B (2010) Expanded newborn screening: reducing harm, assessing benefit. J Inherit Metab Dis 33(Suppl 2):S205-S210
60. Wilson JM, Jungner G (1968) Principles and practice of screening for disease. Public health papers 34. World Health Organization, Geneva, pp 1-163
61. Working Party of the Clinical Genetics Society (UK) (1994) The genetic testing of children. J Med Genet 31:785-797